Biovista is pleased to announce the appointment of a Business Development Agent in Japan. Based in Tokyo, our BD Agent will serve Biovista customers and collaborators throughout Japan. Our agent will focus on Biovista’s new therapy development services and will serve as the main contact point for our Japanese customers. Additionally, our Agent will support … Read More
Customer experience is emerging as a valuable and defensible differentiator for vendors in the life science reagent market. In the past, product quality and price were the two criteria that strongly determined purchase decisions. But this is no longer the case. Many vendors are already competing on price and at the same time reacting to the increasing pressure … Read More
Biovista is pleased to announce that its patent application for the use of tetracyclic pyrazinoindoles has issued in the EU. This new patent (European patent No.: 2375900) has title “METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRZINOINDOLES” was issued on March 2, 2016.
By Andreas Persidis, CEO Biovista Inc. Are you by any chance, like me, beginning to get the feeling that when you are searching online, your digital profile may be getting in the way? That too much of this “personalized” cerebral pampering, too much of this “right information, to the right person at the right time” … Read More
Why Systematic Drug Repurposing (SDR) is here to stay. The article gives 5 reasons why SDR will continue to be used as a tool for developing new therapies that are more affordable and make better use of our existing knowledge of disease pathology, drug performance and other date from the real world evidence surrounding treatments.